SynthesisFrontiers in oncology2025

Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer: a systematic review and meta-analysis.

Xuefeng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.